Aragon Pharmaceuticals Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (2009)
Status: Acquired by Johnson and Johnson (2013)

Organization Overview

First Clinical Trial
2010
NCT01171898
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Aragon Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypersensitivity (Phase 2)

Liver Diseases (Phase 1)

Prostatic Neoplasms (Phase 3)

Prostatic Neoplasms, Castration-Resistant (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 17